What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2025-02-25 compared with 2024-02-27 · 158 added, 152 removed, 151 unchanged (67% of the section changed)

3 unchanged sentences

As of December 29, 2024, we employed approximately 11,000 employees.

Effective as of April 26, 2023, we changed our name from PerkinElmer, Inc.

to Revvity, Inc.

Effective as of May 16, 2023, we changed the ticker symbol for our common stock to “RVTY” and the ticker symbol for our 1.875% Notes due 2026 to “RVTY 26”.

Our common stock is listed on the New York Stock Exchange under the symbol “RVTY” and we are a component of the S&P 500 Index.

11 unchanged sentences

• Opportunistically utilizing our share repurchase programs to help drive shareholder value.

Recent Developments

As part of our strategy to grow our core businesses and transform our portfolio, we have recently taken the following actions:

Discontinued Operations in Fiscal Year 2023:

On March 13, 2023, we completed the previously announced sale (the “Closing”) of certain assets and the equity interests of certain entities constituting our Applied, Food and Enterprise Services businesses (the “Business”) to PerkinElmer Topco, L.P.

(formerly known as Polaris Purchaser, L.P.) (the “Purchaser”), a Delaware limited partnership owned by funds managed by affiliates of New Mountain Capital L.L.C.

(the “Sponsor”), for an aggregate purchase price of up to $2.45 billion.

We received approximately $2.13 billion in cash proceeds, before transaction costs and subject to post-closing adjustments.

We are entitled to an additional $75.0 million in proceeds as consideration for our ceasing the use of the PerkinElmer brand and related trademarks and transferring them to the Purc haser.

This consideration is expected to be received in installments through the first half of 2025.

In addition, we are entitled to additional consideration of up to $150.0 million that is contingent on the exit valuation the Sponsor and its affiliated funds receive o n a sale or other capital events related to the Business.

Business Segments and Products

5 unchanged sentences

Our offerings span the areas of cell, gene, and protein research, enabling scientists to work smarter, make research breakthroughs, and transform those breakthroughs into real-world outcomes.

We partner with global pharmaceutical, biotech and contract research organizations, as well as academic institutions, to enable them to discover and develop better treatments and therapeutics to fight disease faster and more efficiently.

We partner with global pharmaceutical, biotech and contract research organizations, as well as academic and government institutions, to enable them to discover and develop better treatments and therapeutics to fight disease faster and more efficiently.

Principal Products:

Our principal products and services for Life Sciences applications include the following:

• Radiometric detection solutions, including over 750 radiochemicals and instrumentation such as the Tri-Carb ® and Quantulus ™ GCT families of liquid scintillation analyzers, Wizard 2® Gamma counters and MicroBeta 2® plate based LSA, which are used for beta, gamma and luminescence counting in microplate and vial formats utilized in research, environmental and drug discovery applications.

• The Opera Phenix ® Plus high-content screening system, which is used for sensitive and high-speed phenotypic drug screening of complex cellular models.

• The Operetta ® CLS ™ high-content analysis system, which enables scientists to reveal fine sub-cellular details from everyday assays as well as more complex studies, for example using live cells, 3D and stem cells.

◦ Radiometric detection solutions, including over 750 radiochemicals and instrumentation such as the Tri-Carb ® and Quantulus ® GCT families of liquid scintillation analyzers, Wizard 2TM Gamma counters and MicroBeta 2TM plate based LSA are used for beta, gamma and luminescence counting in microplate and vial formats utilized in research, environmental and drug discovery applications.

◦ Reagents and solutions for microscopy and imaging applications.

These include PhenoVue™ cellular imaging reagents and cell painting kits, PhenoPlate (formerly CellCarrier Ultra™) cellular imaging microplates and GrowDex ® hydrogels, fluorophore-conjugated and enzyme-conjugated antibodies, as well as buffers and solutions, such as our Ce3D™ collection of buffers for 3D tissue imaging.

• The MuviCyte™ live-cell imaging system, designed to operate inside a cell-culture incubator, enabling researchers to study cellular behaviors and pathways in living cells to gain a deeper understanding of functions, disease mechanisms and responses to treatments.

• The Signals Image Artist™ next-generation image analysis and management platform for drug discovery research, to help scientists process and analyze high-content screening (HCS) and cellular imaging data in a matter of hours versus days or weeks, so they can make more informed decisions faster.

• The VICTOR Nivo ® multimode plate reader benchtop system, which is designed for assay development and academic labs, including those using HTRF ® and AlphaLISA ® assay technologies.

• The EnSight ® multimode plate reader benchtop system, which offers well plate imaging alongside labeled detection technologies for target-based and phenotypic assays.

• The EnVision ® multimode plate reader, which is designed for high-throughput screening laboratories, including those using HTRF ® , AlphaScreen ® and AlphaLISA ® assay technologies.

• A wide range of homogeneous biochemical and cell-based reagents using HTRF ® , LANCE ® Ultra™, DELFIA ® , AlphaLISA ® , AlphaLISA ® SureFire ® Ultra, AlphaScreen ® , AlphaPlex ® and luminescence assay technologies.

These include PhenoVue ® cellular imaging reagents and cell painting kits, PhenoPlate (formerly CellCarrier Ultra™) cellular imaging microplates and GrowDex TM hydrogels, fluorophore-conjugated and enzyme-conjugated antibodies, as well as buffers and solutions, such as our Ce3D™ collection of buffers for 3D tissue imaging.

◦ A wide range of homogeneous biochemical and cell-based reagents using HTRF®, LANCE® Ultra™, DELFIA®, AlphaLISA®, AlphaLISA® SureFire® Ultra™, AlphaScreen®, AlphaPlex® and luminescence assay technologies that can be paired with our microplates, which cover a variety of applications.

◦ New assay kits for Adeno-associated Virus Vectors (AAVs) and gene therapy applications in our range of HTRF ® and AlphaLISA ® reagents, for detecting and quantifying CHO HCP impurities in biotherapeutics development, as well as kits across oncology, neuroscience, and targeted protein degradation applications.

◦ A broad portfolio of recombinant GPCR and ion channel cell lines, including over 300 products and 120 ready-to-use frozen cell lines for a wide range of disease areas.

◦ Dharmacon ® reagents and gene modulation technologies such as RNAi that support drug discovery and development for greater understanding of gene function, identifying genetic drivers behind human disease, developing and validating diagnostic workflows, and helping deliver biotherapeutics, cellular and gene therapies for precision medicine with a portfolio of cell engineering tools.

◦ BioLegend ® ELISA MAX™ Standard Sets, ELISA MAX™ Deluxe Sets, LEGEND MAX™ ELISA Kits, and RAPID MAX™ ELISA Kits as well as complementary solutions and buffers for immunoassays to cover more than 200 targets for human, mouse, and rat samples, many of which are designed to assess the immune environment and its inflammatory state for vaccine, infectious disease and autoimmune disease research.

• BioLegend ® LEGENDplex™ bead-based reagents, which, in contrast to single analyte assays such as enzyme-linked immunosorbent assays (“ELISAs”), can quantitate up to 14 targets, from one small sample volume in a flow cytometry assay, and include both desktop and cloud-based analysis software.

• In vivo imaging technologies and reagents for preclinical research, comprised of the IVIS ® Spectrum ™ series for 2D and 3D optical imaging and optionally integrated low-dose CT imaging and the IVIS ® Lumina ™ series for benchtop 2D imaging, along with IVISbrite™ bioluminescent and IVISense™ fluorescent imaging agents, cell lines and dyes.

• The Quantum TM GX2 system, which enables low-dose in vivo CT imaging of multiple species and areas of anatomical interest across multiple disease areas by way of high-resolution, tomographic imaging.

• GoInVivo™ as well as Ultra-LEAF™ and LEAF™ functional antibodies, which provide an affordable solution for researchers performing in vivo and ex vivo studies.

• Nexcelom BioScience high-throughput, microwell Celigo ® image cytometry system, Cellaca™ MX high-throughput cell counter, the new Cellaca™ PLX image cytometry system, and Cellometer ® automated cell counters, complemented by consumables and reagents, including reagents and kits for cell counting assays and cell viability, microplates, slides, and counting beads.

• Mimix Reference Standards, which are cell line-derived and suitable for Next Generation Sequencing, droplet-digital and Real-Time PCR as well as Sanger sequencing.

The platform is agnostic for seamless integration into any quality control workflow.

• Dharmacon™ Reagents and gene modulation technologies such as RNAi that support drug discovery and development for greater understanding of gene function, identify genetic drivers behind human disease, develop and validate diagnostic workflows, and help deliver biotherapeutics, cellular and gene therapies for precision medicine with a portfolio of cell engineering tools.

• Pin-point™ base editing platform, which is a CRISPR-Cas9-based technology that allows researchers to make precision base changes in genomic DNA.

Editing with such precision can be used to silence disease-causing genes, correct disease-associated mutations, and optimize cell therapies.

• CHOSOURCE™ platform, which was expanded to include CHO-K1 ADCC+ expression cell line for development of therapeutic antibodies in oncology, infectious disease and autoimmune conditions.

• BioLegend ®’ s catalog of more than 20,000 SKUs, incorporating antibodies and a large collection of antibody conjugates and modifications as well as recombinant proteins, immunoassays and other supportive reagents and solutions for cell and molecular analysis.

• The T-SPOT ® Discovery SARS-CoV-2 research-use-only assay to investigate cell-mediated immunity related to COVID-19.

• Sirion Biotech consultancy services and technologies to design and manufacture viral vectors for cell and gene therapy research and preclinical development.

• BioLegend ® best-in-class antibodies, recombinant proteins and related reagents, which are used across multiple applications and research areas, including proteogenomics, tissue, cell and protein analysis, cancer research, immunology, cell and gene therapy, stem cell therapy and neuroscience.

• Fluorophore-conjugated antibodies, which are used in flow cytometers to characterize protein expression on the surface and in internal compartments of cells.

◦ BioLegend ® LEGENDplex™ bead-based reagents, which, in contrast to single analyte assays such as enzyme-linked immunosorbent assays (“ELISAs”), can quantitate up to 14 targets from one small sample volume and read on common flow cytometers, and include both desktop and cloud-based analysis software.

◦ BioLegend ® best-in-class antibodies, recombinant proteins, and related reagents are used across multiple applications and research areas, including proteogenomics, tissue, cell and protein analysis, cancer research, immunology, cell and gene therapy, stem cell therapy and neuroscience.

◦ Fluorophore-conjugated antibodies are used in flow cytometers to characterize protein expression on the surface and in internal compartments of cells.

The large collection of dyes and antibodies allows for an increasing number of conjugate options, facilitating the use of bigger and better flow cytometry panels using conventional and spectral flow cytometers.

Notable products are Brilliant Violet™ and the Spark™ and Fire dye series, among others.

• BioLegend ® TotalSeq™ reagents, which are oligonucleotide-barcoded antibodies that enable protein detection by sequencing that can be combined with traditional RNA or DNA sequencing experiments with high-parameter protein detection, including comprehensive cloud-based analysis software.

Notable products are Brilliant Violet™ and the Spark and Fire TM dye series, among others.

◦ BioLegend ® TotalSeq™ reagents are oligonucleotide-barcoded antibodies that enable protein detection to be combined with traditional RNA or DNA sequencing experiments with high-parameter protein detection.

Data can be analyzed with their complimentary and comprehensive cloud-based Multiomics Analysis Software.

◦ Cell culture and biofunctional assay reagents, including bioactive recombinant proteins, as well as other specialized reagents such as Cell-Vive™ T-NK Xeno-Free Serum Substitute (compliant with Good Manufacturing Practice requirements (“GMP”)), and other GMP-produced recombinant proteins and reagents.

These products serve several markets, notably cell and gene therapy applications.

• BioLegend ®’ s MojoSort™ and Lymphopure™ reagents for cell separation that complement our fluorophore-antibody conjugates, used for FACS (Fluorescence-activated Cell Sorting), thus covering most cell separation and cell sorting technologies and applications.

◦ BioLegend ® ’s MojoSort™ for cell separation that complements our fluorophore-antibody conjugates, used for FACS (Fluorescence-activated Cell Sorting), thus covering most cell separation and cell sorting technologies and applications.

◦ BioLegend’s catalog of more than 33,000 SKUs, incorporating antibodies and a large collection of antibody conjugates and modifications as well as recombinant proteins, immunoassays, and other supportive reagents and solutions for cell and molecular analysis.

◦ Flex-T™ reagents that utilize peptide-loaded major histocompatibility molecules assembled into tetramers for the identification of antigen-specific T cells.

Our Flex-T products can be used to screen the efficacy of antigen peptides for vaccine and drug trials, as well as characterize the dominance of cancer-specific self-peptides, and more recently, SARS-CoV-2 peptides for COVID-19 research.

• Antibodies and solutions for Western blotting.

A large collection of validated antibodies, as well as supporting buffers and substrates, which provide a convenient set of tools to characterize protein size and relative expression levels in cell or tissue lysates.

• Signals Research Platform, which equips pharmaceutical scientists with the essential tools to gather, search, mine, analyze and visualize critical data, yielding actionable insights in an automated, predictive, and scalable manner.

Within life science research and development and clinical research applications, our software accelerates innovation, development, collaboration and research, ultimately leading to life-enhancing medical breakthroughs more quickly, promoting our vision of a healthier humankind.

In addition, it also empowers scientists and formulators in specialty chemical and food sciences to analyze food, and additives, and create high-performing materials that align with sustainability initiatives, promoting energy efficiency, lower toxicity and a circular economy.

• Signals Notebook, a secure cloud-native electronic lab notebook (ELN) for chemistry, biology, research, and formulations.

From increased collaboration to securely accessible data, Signals Notebooks accelerates research and development workflows, increases collaboration, integrates with Microsoft Office and more.

• Signals ChemDraw ® , which since 1985 has provided solutions with powerful capabilities and integrations to help quickly turn ideas and drawings into publications.

Signals ChemDraw automates chemical drawings and transforms them into chemical knowledge by facilitating the management, reporting and presenting of chemistry research.

• Signals Clinical, which provides a single unified platform to support data access, preparation and analytics, from source to visualization to action.

With unrivaled workflow flexibility to support dynamic collaboration, Signals Clinical’s SaaS solution helps accelerate the delivery of urgently needed therapeutics to patients.

• Vega ® preclinical ultrasound system, a hands-free, automated, high-throughput imaging system delivering high-resolution 2D and 3D ultrasound images in minutes.

Originally launched in North America in 2022, it is now globally available.

• New assay kits for Adeno-associated Virus Vectors (AAVs) and gene therapy applications in our range of HTRF ® and AlphaLISA ® reagents, for detecting and quantifying CHO HCP impurities in biotherapeutics development, as well as kits across oncology, neuroscience, and targeted protein degradation applications.

• Cellaca PLX™ image cytometry system, which combines best-in-class image cytometer hardware, software, validated consumables and optimized reagent kits with validated antibodies from our BioLegend business, and trackable data reporting to enable the simultaneous detection of multiple markers and to streamline cell and gene therapy workflows.

• New fluorescent stains, reagents and secondary antibodies in our PhenoVue TM cellular imaging reagents portfolio for the detection and analysis of cellular components.

• The latest version of the Signals Image Artist™ next-generation image analysis and management platform, which provides improved 3D cell segmentation and analysis, an AWS S3 cloud deployment option and enhanced cloud security, and compatibility with a broader range of systems, including the Nexcelom from Revvity Celigo ® image cytometer.

• An updated VICTOR ® Nivo™ multimode plate reader with a new software version for streamlined data analysis.

◦ Antibodies and solutions for Western blotting, as well as supporting buffers and substrates, provide a convenient set of tools to characterize protein size and relative expression levels in cell or tissue lysates.

◦ Mimix TM reference standards are cell line-derived to mimic patient samples and suitable for next generation sequencing, droplet-digital and real-time PCR as well as Sanger sequencing.

The platform is agnostic for seamless integration into quality control workflows.

◦ OptiScint™ NPE-free scintillation cocktails and quench standards, providing a more environmentally friendly alternative without compromising performance.

◦ Expansion of our Western blotting reagents with the addition of the Western Lightning™ One range, which has a pre-mixed one component chemiluminescent HRP substrate for more consistent results.

• Additional Spark™ and Fire dye-conjugated antibodies, enabling higher-parameter flow cytometry.

Notable products are the Spark UV™ 387 and Spark Red™ 718 conjugates.

◦ Additional Spark and Fire TM dye-conjugated antibodies, enabling higher-parameter flow cytometry.

Notable products are the Spark PLUS UV395™ and Spark PLUS B550™ conjugates.

◦ For the TotalSeq ™ reagent portfolio, more large panels of pre-titrated oligo-conjugated antibodies released in universal panels for the analysis of human and mouse samples.

• Software solutions for BioLegend ® LEGENDplex™ assays, multiomics analysis with TotalSeq reagents, and flow cytometry-based cell analysis software (Ryvett) that are now part of BioLegend’s data integration offerings.

New options were created for intracellular target staining and protein-only analysis.

◦ New fluorescent stains, reagents and secondary antibodies in our PhenoVue TM cellular imaging reagents portfolio for the detection and analysis of cellular components.

◦ GoInVivo™ as well as Ultra-LEAF™ and LEAF™ functional antibodies provide an affordable solution for researchers performing in vivo and ex vivo studies.

• Instruments

◦ The Opera Phenix ® Plus high-content screening system for sensitive and high-speed phenotypic drug screening of complex cellular models.

◦ The Operetta ® CLS™ high-content analysis system enables scientists to reveal fine sub-cellular details from everyday assays as well as more complex studies, for example using live cells, 3D and stem cells.

◦ The VICTOR Nivo TM multimode plate reader benchtop system designed for assay development and academic labs, including those using HTRF® and AlphaLISA® assay technologies.

◦ The EnVision TM multimode plate reader designed for high-throughput screening laboratories, including those using HTRF®, AlphaScreen® and AlphaLISA® assay technologies.

◦ The EnVision Nexus TM multimode plate reader, our next generation system for high-throughput screening with advanced detection technologies for Alpha, TRF, and Luminescence.

◦ In vivo optical imaging platforms and reagents for preclinical research, comprised of the IVIS ® Spectrum™ series for 2D and 3D optical imaging and optionally integrated low-dose CT imaging and the IVIS ® Lumina™ series for benchtop 2D imaging, along with IVISbrite ® bioluminescent and IVISense ® fluorescent imaging agents and imaging reagents.

◦ The Quantum TM GX3 system, which enables low-dose in vivo CT imaging of multiple species and areas of anatomical interest across multiple disease areas by way of high-resolution, tomographic imaging.

◦ The Vega™ ultrasound system, a hands-free automated ultrasound platform delivers high-resolution 2D and 3D imaging in just a few minutes.

This innovative in vivo ultrasound system removes the challenges associated with conventional hand-held systems through the use of automated transducers located under the imaging stage and is easy to use, requires minimal training and produces more consistent results.

It is complemented by GoInVivo™ as well as Ultra-LEAF™ and LEAF™ functional antibodies providing an affordable solution for researchers performing in vivo and ex vivo studies.

◦ The high-throughput, microwell Celigo ® image cytometry system, the Cellaca ® MX high-throughput cell counter, the Cellaca ® PLX image cytometry system, and the Cellometer ® automated cell counters, complemented by consumables and reagents, including reagents and kits for cell counting assays and cell viability, microplates, slides, and counting beads.

◦ Cellaca ® PLX™ image cytometry system combines best-in-class image cytometer hardware, software, validated consumables and optimized reagent kits with validated antibodies from our BioLegend business, and trackable data reporting to enable the simultaneous detection of multiple markers and to streamline cell and gene therapy workflows.

◦ The Signals Image Artist™ next-generation image analysis and management platform for drug discovery research, to help scientists process and analyze high-content screening (HCS) and cellular imaging data in a matter of hours versus days or weeks, so they can make more informed decisions faster.

◦ Signals Research platform equips pharmaceutical scientists with the essential tools to gather, search, mine, analyze and visualize critical data, yielding actionable insights in an automated, predictive, and scalable manner.

Within life science research and development and clinical research applications, our software accelerates innovation, development, collaboration and research, ultimately leading to accelerated life-enhancing medical breakthroughs, promoting our vision of a healthier humankind.

In addition, it also

empowers scientists and formulators in specialty chemical and food sciences to analyze food, and additives, and create high-performing materials that align with sustainability initiatives, promoting energy efficiency, lower toxicity and a circular economy.

◦ The Signals Notebook TM secure cloud-native electronic lab notebook (ELN) for chemistry, biology, research, and formulations.

From increased collaboration to securely accessible data, the Signals Notebook TM offering accelerates research and development workflows, increases collaboration, integrates with Microsoft Office and more.

◦ Signals ChemDraw ® software providing solutions with powerful capabilities and integrations to help quickly turn ideas and drawings into publications since 1985.

Signals ChemDraw ® software automates chemical drawings and transforms them into chemical knowledge by facilitating the management, reporting and presenting of chemistry research.

◦ Signals Clinical offering provides a single unified platform to support data access, preparation and analytics, from source to visualization to action.

With unrivaled workflow flexibility to support dynamic collaboration, Signals Clinical’s SaaS solution helps accelerate the delivery of urgently needed therapeutics to patients.

◦ Signals DLX™ powered by Scitara ® establishes seamless, bidirectional connectivity across instruments, LIMS, ELNs and other critical lab systems that previously existed in isolation.

◦ The latest version of the Signals Image Artist™ next-generation image analysis and management platform provides improved 3D cell segmentation and analysis, an AWS S3 cloud deployment option and enhanced cloud security, and compatibility with a broader range of systems, including the Nexcelom from Revvity Celigo ®TM image cytometer.

◦ An updated VICTOR Nivo™ multimode plate reader with a new software version for streamlined data analysis.

◦ Software solutions for BioLegend ® LEGENDplex ™ assays and multiomics analysis with TotalSeq™ reagents, that are now part of BioLegend’s data integration offerings.

• Technology and Licensing

◦ The Pin-point™ base editing platform is a CRISPR-Cas9-based technology that allows researchers to make precision base changes in genomic DNA.

Editing with such precision can be used to silence disease-causing genes, correct disease-associated mutations, and optimize cell therapies.

◦ CHOSOURCE™ platform was expanded to include a CHO-K1 ADCC+ expression cell line for development of therapeutic antibodies in oncology, infectious disease and autoimmune conditions.

◦ Gene Delivery services and technologies to design and manufacture viral vectors for cell and gene therapy research and preclinical development.

This includes LentiBOOST ® transduction enhancer technology for improved lentiviral transduction efficiency, helping to reduce the cost of goods for cell therapies.

◦ Preclinical services for oncology, leveraging capabilities such as cell panel screening, cell line engineering, functional genomic screening, and immune cell screening, for a range of applications to help accelerate the drug development process.

New Products:

New products introduced or acquired for Life Sciences applications in fiscal year 2024 include the following:

• Pin-point TM base editing reagents, which improve access to new-generation editing technology.

The launch of these reagents puts clinically relevant base editing using the Pin-point platform in the hands of preclinical laboratories seeking to accelerate genomic insights and cell therapy research.

• IVIS ® Spectrum 2 and IVIS SpectrumCT 2 next-generation imaging systems, our newest flagship platforms setting the standard in high-throughput performance and versatility.

• Quantum TM GX3 microCT imaging solution, a high-throughput system with superior spatial resolution and fast, low-dose scanning for diverse in vivo and biological ex vivo applications.

With class-leading resolution, the system is designed for a wide applications, including bone imaging.

• Signals Research Suite, a unified, cloud-native SaaS platform that drives scientific collaboration across research and development disciplines from drug discovery to specialty chemicals material development.

• Signals DLX™ powered by Scitara ®, , which establishes seamless, bidirectional connectivity across instruments, LIMS, ELNs and other critical lab systems that previously existed in isolation.

◦ Biolegend launched new dyes to expand flow cytometry panel building options, including PE/Fire™ 744, Spark PLUS UV395™, Spark PLUS™ B550 antibody conjugates and Zombie UV387™ for dead cell analysis.

In addition, the Flexi-Fluor™ portfolio of reagents was created as a made-to-order, rapid alternative to traditional custom products.

◦ Oligo-conjugated antibodies for intracellular detection of proteins and cytokines introduced in BioLegend's TotalSeq TM portfolio.

BioLegend also introduced a solution for high-throughput, high-parameter single-cell protein analysis - TotalSeq™ PhenoCyte TM .

PhenoCyte TM provides a streamlined, instrument-free workflow for scalable single-cell immunoprofiling.

• Instruments

◦ The Cellometer ™ Ascend™ automated cell counter accelerates lab workflow by mitigating human error, all while providing a consistent, standardized cell count.

Incorporated with its user-friendly Matrix software, this product performs an automated and sophisticated image analysis workflow that delivers reliable results in seconds.

◦ Phenologic.AI ™ software, a module in our Harmony™ high-content imaging and analysis software and in our Signals Image Artist™ image analysis and data management platform uses a pre-trained deep-learning image-analysis model to enable analysis of brightfield images and provides an additional channel for multiplexing and easier analysis of live cell assays.

Our Life Sciences segment offers additional products under various brand names:

Accell™, AdenoBOOST™, AlphaLISA ® , AlphaPlex ™ , AlphaScreen ® , Alpha™ SureFire ® , Brilliant Violet™, Ce3D™, CellCarrier ® , Cellaca™, Celigo ® ™, Cellometer ® ™, cell::explorer ™ , Cell-Vive™, Chalice™, Chem3D ® , ChemDraw ® , ChemOffice ® , CHOSOURCE™, Dharmacon™, DharmaFECT™, Edit-R™, ELISA MAX™, EnSight ® , EnVision ® , Flex-T™, FMT ® , FolateRSense ™ , GoInVivo™, HTRF®, IVIS ® , IVISbrite™, IVISense™, LANCE ® , LANCE ® Ultra ™, LEAF™, LEGEND MAX™, LEGENDplex™, LentiBOOST™, Lincode™, Living Image ® , Lumina™, Lymphopure™, MicroBeta 2® , Mini ELISA Plate Reader™, miRIDIAN™, MojoSort™, MuviCyte™, ON-TARGET™, ON-TARGETplus™, Opera Phenix ® Plus, Operetta ® CLS™, OptiScint™, PhenoPlate™, PhenoVue™, Pin-point™, Quantulus ™ GCT, RAPID MAX™, RediJect™, RNAiONE™, Signals™, Signals Image Artist™, SMARTpools ™ , SMARTvector ™ , Spark™, Spectrum™, TotalSeq™, Tri-Carb ® , T-SPOT ® , Ultra-LEAF™, Vega®, VesselVue ® , ViaStain™, VICTOR Nivo ™ Western Lightning ™ and Wizard 2® .

Accell™, AdenoBOOST™, AlphaLISA ® , AlphaPlex ™ , AlphaScreen ® , Alpha™ SureFire ® , BioLegend ® , Brilliant Violet™, Ce3D™, CellCarrier ® , Cellaca™, Celigo™, Cellometer™, cell::explorer ™ , Cell-Vive™, Chalice™, Chem3D ® , ChemDraw ® , ChemOffice ® , CHOSOURCE™, DELFIA ® , Dharmacon™, DharmaFECT™, Edit-R™, ELISA MAX™, EnVision TM , EnVision Nexus TM , Flex-T™, FMT ® , FolateRSense ™ , GoInVivo™, HTRF ® , ImmuSignature ™ , IVIS ® , IVISbrite ® , IVISense ® , LANCE ® , LANCE ® Ultra ™, LEAF™, LEGEND MAX™, LEGENDplex™, LentiBOOST ® , Lincode™, Living Image ® , Lumina™, MicroBeta TM , Mimix TM , Mini ELISA Plate Reader™, miRIDIAN™, MojoSort™, MuviCyte™, NEN ® , OncoSignature™, OncoSpan TM , ON-TARGET™, ON-TARGETplus™, Opera Phenix TM Plus, Operetta-CLS™, OptiScint™, PhenoPlate™, PhenoVue™, Pin-point™, Quantulus ™ GCT, Quantum™, RAPID MAX™, RediJect™, RNAiONE™, Signals™, Signals Image Artist™, SMARTpools ™ , SMARTvector ™ , Spark PLUS™, Spectrum™, TotalSeq™, Tri-Carb TM , Ultra-LEAF™, Vega TM , VesselVue ® , ViaStain™, VICTOR Nivo ™ , Western Lightning ™ , and Wizard2 TM .

Diagnostics Segment

7 unchanged sentences

Our principal products and services for Diagnostics applications include the following:

• The DELFIA ® Xpress screening platform, a complete solution for prenatal and maternal health screening, which includes a fast continuous loading system.

• Reproductive Health

◦ The DELFIA ® Xpress screening platform, a complete solution for prenatal and maternal health screening including a fast continuous loading system.

It is supported by kits for first, second and third trimester analyses for prenatal screening and clinically validated LifeCycle™ software.

• The DELFIA ® Xpress sFlt-1 kit, which enables short term prediction of pre-eclampsia and aids in diagnosis in the second and third trimesters of pregnancy together with the previously launched DELFIA ® Xpress PlGF 1-2-3™ assay.

• The NeoBase™ non-derivatized MS/MS AAAC kits, which are used to support detection of metabolic disorders in newborns through tandem mass spectrometry.

◦ The DELFIA ® Xpress sFlt-1 kit enables short term prediction of pre-eclampsia and aids in diagnosis in the second and third trimesters of pregnancy together with the previously launched DELFIA ® Xpress PlGF 1-2-3™ assay.

◦ The NeoBase™ non-derivatized MS/MS AAAC kits is used to support detection of metabolic disorders in newborns through tandem mass spectrometry.

The kits analyze newborn dry blood spot samples for measurement of amino acids and other metabolic analytes for specific diseases.

2 unchanged sentences

◦ The NeoLSD™ MS/MS kit, the first commercial IVD kit for screening of Pompe, MPS-I, Fabry, Gaucher, Niemann-Pick A/B and Krabbe disorders from a single dried blood spot sample.

• QSight ® 210MD and 225MD UHPLC MS/MS instruments, which are used for newborn screening.

◦ QSight ® 210MD and 225MD UHPLC MS/MS instruments used for newborn screening.

◦ Vanadis® NIPT, a non-PCR non-sequencing fully automated cfDNA technology for use in any laboratory for screening common trisomies in the pregnant population.

◦ The EONIS™ assay, a CE marked and United States Food and Drug Administration (“FDA”) authorized system utilizing real-time PCR technology, which allows for simultaneous screening of SMA, SCID and XLA in newborns from a single DBS punch.

◦ EONIS™ Q novel “dry-chemistry” qPCR newborn screening workflow for SCID, SMA, and XALD screening.

◦ DELFIA™ Trio automated plate dispenser, washer and disk remover for the manual newborn screening and prenatal workflows.

◦ EVOYA ® cloud-based, newborn screening, informatics and data management software.

◦ ViaCord ® umbilical cord blood banking services for the banking of stem cells harvested from umbilical cord blood and cord tissue, for potential therapeutic application in transplant and regenerative medicine.

◦ Revvity Omics global laboratory network offering multi-OMIC clinical grade services for testing over an individual’s lifetime (prenatal to adults) in cytogenetics, biochemical genetics, molecular genetics and immunodiagnostics.

The laboratory network includes testing laboratories in the United States, Sweden, India, China and the United Kingdom.

◦ Utilizing next-generation sequencing, Revvity Omics labs provide testing solutions including but not limited to whole genome sequencing, whole exome sequencing, curated and customized gene panels.

◦ Revvity Omics Whole Genome Sequencing test provides dual genome analysis (nuclear and mitochondrial) detecting single nucleotide variants, chromosomal and intragenic copy number events, short tandem repeats analysis for >30genes and SMN1 copy number characterization.

This test also provides additional findings like pharmacogenomic analysis and carrier status among others.

◦ Ultrarapid Whole Genome Sequencing test, a variant of the whole genome sequencing (WGS) analysis, bundles the StepOne biochemical profile, cCMV analysis and metagenomic analysis with the standard WGS analysis to help babies in the NICU with a result as fast as five days.

◦ Using WGS as a backbone, Revvity Omics provides two unique products, the CNGnome® NGS Array and WholePanel ™ test.

Utilizing the uniform coverage across genome, the CNGnome NGS array is used to detect copy number events over 25kb in size, making this as a new gold standard in CNV detection.

The WholePanel test provides enhanced coverage including the intronic regions for the expertly curated WholeCancer, WholeAtaxia, WholeCardiology and WholeMuscularDystrophy gene panels.

• Applied Genomics

◦ The Omni Bead Ruptor ® Elite Bead Mill Homogenizer enables grinding, lysing, and homogenization of biological samples prior to molecular analyte extraction, delivering repeatable sample disassociation.

◦ The Omni Prep 96 Automated Homogenizer Workstation, a fully automated homogenizer enabling true walk-away processing for high-throughput labs.

◦ Automated liquid handling platforms (Fontus™, JANUS®, Sciclone®, Zephyr® and FlexDrop™) offering a choice of robotic solutions in genomics, biotherapeutics, high throughput screening and high content analysis to assist life science research from bench to clinic.

◦ JANUS ® BioTx™ and PreNAT II™ workstations for automated small-scale purification, offering column, tip and plate-based chromatography on a single platform.

◦ The LabChip® GXII Touch™ protein characterization system provides a means of characterizing multiple protein product attributes for research labs through QC.

◦ The explorer™ automated workstation allows integration of multiple laboratory instrumentation using a centralized robotic interface, allowing high throughput and turnkey-application focused solutions.

◦ The PG-Seq™ Rapid kit v2 analyzes picogram quantities of DNA from an embryo biopsy for preimplantation genetic research with enhanced whole genome coverage and accuracy.

◦ DOPlify ® WGA V2 kit performs fast whole genome amplification on single cells or limited template DNA samples, allowing cell chromosome copy number status to be determined.

◦ NEXTFLEX ® library prep kits simplify library prep with optimized protocols and reagents, making the library preparation process more efficient and reliable.

◦ Automation protocols and kits launched for the BioQule™ NGS System, making it an open system that combines automation, reagents, consumables and scripts, enabling walkaway automation to simplify low throughput nucleic acid isolation, NGS library preparation and quantitation.

◦ The Fontus™ liquid handler is available in multiple versions to automate both NGS and life science workflows.

• Immunodiagnostics

◦ The chemagic™ Prime™ instrument is a fully automated, LIMS-compatible solution for primary sample transfer, DNA and RNA isolation, to normalization and the setup of PCR and Next Generation Sequencing (“NGS”) applications.

◦ The chemagic™ 360 instrument is a flexible solution for automated nucleic acid isolation from 0.1-18 ml sample volumes of diverse sample materials.

The chemagic™ 360-D instrument (IVDR) and chemagic™

Prime™ Junior-D instrument (IVDR), together with the chemagic™ IVD Kits, are the optimal choice for automated IVDR compliant nucleic acid isolation for clinical diagnostics.

◦ The Oxford Immunotec T-SPOT ® Technology platform, a modified ELISPOT used to detect a T cell immune response to infection.

◦ The Oxford Immunotec T-SPOT ® TB test, an in vitro diagnostic test for the detection of effector T cells that respond to stimulation by mycobacterium tuberculosis antigens by capturing interferon gamma in the vicinity of T cells in human whole blood.

It is intended for use as an aid in the diagnosis of tuberculosis infection.

◦ An expanded portfolio of molecular-based infectious disease screening technologies for blood bank and clinical laboratory settings in China.

2 unchanged sentences

◦ Chitas ® instrument and HBV/HCV/HIV 3-in-1 PCR reagents for blood screening, and Hi Sensitivity HBV DNA and HCV RNA assays for clinical infectious disease testing.

• The Bead Ruptor™ Elite Bead Mill Homogenizer, which enables grinding, lysing, and homogenizing of biological samples prior to molecular extraction delivering repeatable sample disassociation.

• OMNI Prep 96 Automated Homogenizer Workstation, which is a fully automated homogenization workstation, enabling true walk-away processing.

• The chemagic™ Prime™ instrument, a fully automated, LIMS-compatible solution for primary sample transfer, DNA and RNA isolation, optional normalization and the setup of PCR and Next Generation Sequencing (“NGS”) applications.

• Automated liquid handling platforms (Fontus™, JANUS ® , Sciclone ® , Zephyr ® and FlexDrop™) that offer a choice of robotic solutions in genomics, biotherapeutics, high throughput screening and high content analysis to assist life science research from bench to clinic.

• JANUS ® BioTx ™ and PreNAT II™ workstations for automated small-scale purification, offering column, tip and plate-based chromatography on a single platform.

• HIVE CLX ™ scRNAseq Solution, which integrates sample storage and single cell profiling into a complete workflow, solving the issues that limit single cell RNA analysis.

The LabChip ® GXII Touch ™ protein characterization system, which provides a means of characterizing multiple protein product attributes for research labs through QC.

• The explorer ™ automated workstation, which allows integration of multiple laboratory instrumentation using a centralized robotic interface, allowing high throughput and turnkey-application focused solutions.

• Vanadis ® NIPT, a non-PCR non-sequencing fully automated cfDNA technology for use in any laboratory for screening common trisomies in the pregnant population.

• Revvity Omics, a global laboratory network offering multi-OMIC clinical grade services for testing in cytogenetics, biochemical genetics (prenatal and postnatal), molecular genetics and immunodiagnostics.

The laboratory network includes testing laboratories in the United States, Sweden, India, China and the United Kingdom.

• The EONIS™ assay, a CE marked and United States Food and Drug Administration (“FDA”) authorized system utilizing real-time PCR technology, which allows for simultaneous screening of SMA, SCID and XLA in newborns from a single DBS punch.

• Chemiluminescence immunoassays covering endocrinology, autoimmunity, infectious diseases, allergy and therapeutic drug monitoring.

• ELISAs covering endocrinology, autoimmunity, diabetes monitoring, steroids, thyroid monitoring, animal research and tumor markers.

• Radioactive immunoassays in calcium metabolism.

◦ Chemiluminescence immunoassays and ELISA for therapeutic drug monitoring.

◦ A comprehensive portfolio of chemiluminescence immunoassays and ELISAs for endocrinology testing.

◦ Radioactive immunoassays in testing calcium metabolism.

◦ Autoimmune testing, including indirect immunofluorescence tests (IIFT), ELISA, chemiluminescence immunoassays and immunoblots, covering rheumatology, hepatology, gastroenterology, endocrinology, neurology, nephrology, dermatology and infertility.

• Allergy testing covering allergen-specific immunoglobin E (IgE), measuring the level of different IgE antibodies or total IgE in blood using EUROLINE TM immunoblot assays.

◦ Allergy testing covering allergen-specific immunoglobin E (IgE), measuring the level of different IgE antibodies or total IgE in blood using multiplex EUROLINE TM immunoblot assays as well as singleplex chemiluminescence immunoassays.

◦ Infectious disease testing, including IIFT, ELISA, chemiluminescence immunoassays, immunoblots, microarrays and real-time PCR, covering bacteria, viruses, fungi and parasites.

• A complete portfolio of chemiluminescence immunoassays ( “ ChLIA ” ) for precise Alzheimer’s disease diagnostics, which provides reliable analysis of the established CSF biomarkers beta-amyloid (1-40), beta-amyloid (1-42), total tau and pTau (181) and a high degree of standardization due to fully automated processing.

• EUROLabPolaris, which provides the secure transfer of indirect immunofluorescence data to several locations enabling central evaluation within the software.

• Laboratory management system EUROLabOffice 4.0, which provides a central interface between devices to simplify and speed up the diagnostic routine and increases security through organization of all lab procedures and traceable documentation of all data and processes.

• EUROLabWorkstation IFA and EUROLabWorkstation ELISA, which provide fully automated processing of IIFT and ELISA, respectively, for laboratories with high sample throughput.

• EUROPattern Microscope, which provides fully automated immunofluorescence microscopy including IIFT pattern recognition and titer determination.

• EUROPattern Microscope live, which provides fully automated and fast image recording and modern on-screen reporting, also including IIFT pattern recognition and titer determination.

• EUROBlotOne, a compact tabletop device for complete processing of immunoblots.

• IDS-i10, a compact random access solution for the processing of ChLIA in the field of autoimmune and infection diagnostics as well as antigen detection, providing sample throughput of up to 60 samples per hour.

• IDS-iSYS Multi-Discipline Automated System, which is a compact automation solution for the processing of ChLIA in the field of autoimmune, infection and allergy diagnostics as well as antigen detection, providing sample throughput of up to 120 samples per hour.

• Pre-NAT II, which provides fully automated high-throughput sample preparation for molecular genetic diagnostics, consisting of nucleic acid extraction and subsequent pipetting of the PCRs.

◦ A complete portfolio of chemiluminescence immunoassays (“ChLIA”) for precise Alzheimer’s disease diagnostics providing reliable analysis of the established CSF biomarkers beta-amyloid (1-40), beta-amyloid (1-42), total tau and pTau (181) and a high degree of standardization due to fully automated processing.

◦ EUROLabPolaris platform provides the secure transfer of indirect immunofluorescence data to several locations enabling central evaluation within the software.

◦ EUROLabOffice TM 4.0 laboratory management system provides a central interface between devices to simplify and speed up the diagnostic routine and increases security through organization of all lab procedures and traceable documentation of all data and processes.

◦ EUROPattern Classifier TM 2.4 AI-enhanced software module of EUROLabOffice TM 4.0 offers automated result proposals from images captured with the all-in-one IFA instrument UNIQO 160 as well as from the automated microscopes EUROPattern and EUROPattern Microscope Live.

◦ EUROLabWorkstation TM IFA and EUROLabWorkstation ELISA provide fully automated processing of IIFT and ELISA, respectively, for laboratories with high sample throughput.

◦ EUROPattern TM microscope provides fully automated immunofluorescence microscopy including IIFT pattern recognition and titer determination.

◦ EUROPattern TM microscope live provides fully automated and fast image recording and modern on-screen reporting, also including IIFT pattern recognition and titer determination.

◦ EUROBlotOne TM compact tabletop device for complete processing of immunoblots.

◦ UNIQO160 TM device for fully automated processing of IIFT from primary sample to final microscopy result for up to 160 samples and 18 slides.

◦ IDS-i10 TM compact random-access solution for the processing of ChLIA in the field of autoimmune and infection diagnostics as well as antigen detection, providing sample throughput of up to 170 tests per hour.

◦ IDS-iSYS Multi-Discipline Automated System is a compact automation solution for the processing of ChLIA in the field of autoimmune, infection and allergy diagnostics as well as antigen detection, providing sample throughput of up to 120 samples per hour.

◦ MyFoodProfile immunoblots for the determination of IgG and IgE reactivity against more than 200 foods (CE-marked).

• Prenatal and postnatal testing utilizing Revvity Omics Next Generation Sequencing products including gene panels, exomes and genomes.

• Revvity Omics Whole Genome Sequencing test, which detects duo genome (nuclear and mitochondrial) single nucleotide and copy number variants and includes screening for pharmacogenetic variants, Spinal Muscular Atrophy and more than 30 short tandem repeat disorders.

• Revvity Omics test for Facioscapularhumeral dystrophy (FSHD) using Genome Optical Mapping technology.

• Oxford Immunotec T-SPOT ® Technology platform, a modified ELISPOT used to detect a T cell immune response to infection.

• Oxford Immunotec T-SPOT.TB test, an in vitro diagnostic test for the detection of effector T cells that respond to stimulation by mycobacterium tuberculosis antigens by capturing interferon gamma in the vicinity of T cells in human whole blood.

It is intended for use as an aid in the diagnosis of tuberculosis infection.

• The PG-Seq™ Rapid Kit v2, which analyzes picogram quantities of DNA from an embryo biopsy for preimplantation genetic research with enhanced whole genome coverage and accuracy.

• DOPlify® WGA V2 Kit, which performs fast whole genome amplification on single cells or limited template DNA samples, allowing cell chromosome copy number status to be determined.

• chemagic™ 360-D instrument (IVDR) and chemagic™ Prime™ Junior-D instrument (IVDR) for automated nucleic acid isolation, and related kits such as CE-IVD chemagic™ Nucleic Acid Purification Kits and chemagic™ miRNA 200 Kit.

• Revvity Omics WholePanel test, which is an enhanced panel testing (WholeCancer, WholeAtaxia, WholeCardiology and WholeMuscularDystrophy panels) using genome sequencing as a backbone and provides full intronic coverage and short tandem repeat screening in one test.

• Revvity Omics UltraRapid Whole Genome Sequencing with StepOne, CMV detection and metagenomic analysis, which provides the sickest babies in NICUs with multiomic testing results in five days or less.

New Products:

New products or services introduced or acquired for Diagnostics applications in fiscal year 2024 include the following:

• Fontus™ liquid handler, which is available in multiple versions to automate both NGS and life science workflows.

• EONIS™ Q, a novel “ dry-chemistry ” qPCR newborn screening workflow for SCID and SMA screening.

• DELFIA™ Trio, an automated plate dispenser, washer, disk remover for the manual newborn screening and prenatal workflows.

• EVOYA™, a cloud-based, newborn screening, informatics and data management software.

• Automation protocols and kits launched for the BioQule™ NGS System, making it an open system that combines automation, reagents, consumables and scripts, enabling walkaway automation to simplify low throughput NGS library preparation and quantitation.

• UNIQO160, a device for fully automated processing of IIFT from primary sample to final microscopy result for up to 160 samples and 18 slides.

• 89 new IIFT for the ultrafast automated microscope “ EUROPattern Microscope Live ”.

• Anti-TBE Virus ELISA 2.0 (IgG) and Anti-TBE Virus CSF ELISA 2.0 (IgG) for detection of IgG antibodies against TBE virus in serum and CSF, respectively (CE-marked, IVDR-compliant).

Our Diagnostics segment offers additional products under various brand names, including AutoDELFIA ® , BACS-on-Beads ® , BIOCHIPs, Bioo Scientific ® , BoBs ® , chemagic™, Chitas ® , DELFIA ® , DELFIA ® Xpress, DOPlify ® , EONIS™, EUROArray™ , EUROIMMUN ® , EUROLabWorkstation™, EUROLINE™, EUROPattern TM , Evolution™ Evoya ® , explorer™, Fontus™, Genoglyphix ® , GSP ® , Haoyuan™, IDS ® Immunodiagnosticsystems, IDS-i10 ®, IDS-i10T ® , IDS-iSYS ®, iLab ™ , iQ™, JANUS ® , LabChip ® , LifeCycle ™ , LimsLink ™ , Migele™, MultiPROBE ® , NEXTFLEX ® , NextPrep™, Pannoramic ™ , Panthera Puncher™, PG-Seq™, PG-Find™ PKamp™, PreNAT II™, Prime™, Protein Clear™, ProteinEXact™, QSight ® , QuantiVac™, RONIA™, Sciclone ® , SimplicityChrom™, Specimen Gate ® , Superflex™, Symbio™, T-SPOT ® , Touch™, Twister ® , Vanadis ® , VariSpec ™ , ViaCord ®, VICTOR 2™ D, and Zephyr ® .

• Reproductive Health

◦ CD34+ hematopoietic stem cells from human umbilical cord blood (for research use only and not for use in diagnostic procedures).

◦ The NEXTFLEX ® Neo NGS RUO Panel 1 kit, which is part of a new end-to-end workflow solution for newborn sequencing research.

◦ Revvity Genomics LIMS cloud-based, genomic platform solution is primed for secure data management and LIS integration.

◦ Revvity Genomics Analyze TM genomics primary and secondary analysis software for variant calling.

◦ Revvity Genomics Interpret TM tertiary and reporting software for genomic testing.

◦ Revvity Transcribe AI TM innovative OCR service designed to convert handwritten text on test request forms into a digitized format.

• Applied Genomics

◦ LabChip ® Plasmid DNA assay enables purity and sizing analysis of the three primary isoforms of pDNA during the manufacturing of proteins, viral vectors, and messenger RNA.

• Immunodiagnostics

◦ Auto-Pure TM 2400 automated liquid handling platform designed to provide efficient workflows in the lab for T-SPOT.TB ® testing.

◦ EUROStar IV Plus, a new model of EUROIMMUN's successful LED microscope series for convenient manual fluorescence microscopy with attractive new features for easy and ergonomic manual microscopy.

◦ The optimised (IVDR-compliant) “RVTY” "CSF ELISA 2.0" series for facilitated handling and resource savings.

◦ The GeneProof-ALPCO TM portfolio for molecular diagnostics.

◦ EURORealTime APOE for APOE genotyping to assess a patient’s risk for side effects prior to the start of an anti-amyloid (beta) therapy in Alzheimer’s disease.

Our Diagnostics segment offers additional products under various brand names, including:

AutoDELFIA ® , BACS-on-Beads ® , BIOCHIPs, Bioo Scientific ® , BioQule™, BoBs ® , chemagic™, Chitas ® , DELFIA ® , DELFIA ® Xpress, DOPlify ® , EONIS™, EUROArray™ , EUROIMMUN ® , EUROLabWorkstation™, EUROLINE™, EUROPattern TM , Evolution™ Evoya ® , explorer™, Fontus™, GSP ® , Haoyuan™, IDS ® Immunodiagnosticsystems, IDS-i10 ® , IDS-i10T ® , IDS-iSYS ® , iLab™, iQ™, JANUS ® , LabChip ® , LifeCycle™, LimsLink™, Migele ® , MultiPROBE ® , NEXTFLEX ® , NextPrep™, Omni Bead Ruptor ® , Omni Bead Ruptor Elite™, Omni Tip™, Pannoramic™, Panthera Puncher™, PG-Seq™, PG-Find™, PreNAT II™, Prime™, Protein Clear™, ProteinEXact™, QuantiVac™, RONIA ® , Sciclone ® , SimplicityChrom™, Specimen Gate ® , Superflex™, Symbio™, T-SPOT ® , Touch™, Twister®, Vanadis®, VariSpec™, ViaCord ® , VICTOR2™D, and Zephyr ® .

All of our businesses market their products and services primarily through their own specialized sales forces.

3 unchanged sentences

Each of our businesses uses a wide variety of raw materials, key components and supplies that are generally available from alternate sources of supply and in adequate quantities from domestic and foreign sources.

We generally have multi-year

contracts, with no minimum purchase requirements, with our suppliers.

We generally have multi-year contracts, with no minimum purchase requirements, with our suppliers.

For certain critical raw materials, key components and supplies required for the production of some of our principal products, we have qualified only a limited or a single source of supply.

5 unchanged sentences

We own numerous United States and foreign patents and have patent applications pending in the United States and abroad.

We also license intellectual property rights to and from third parties, some of which bear royalties and are terminable in specified circumstances.

We also license intellectual property rights to and from third parties, some of which bear royalties and are terminable in

specified circumstances.

In addition to our patent portfolio, we possess a wide array of unpatented proprietary technology and know-how.

26 unchanged sentences

In addition, changes in governmental regulations may reduce demand for our products or increase our expenses.

The healthcare industry, including the genetic screening market, is subject to extensive and frequently changing

international and United States federal, state and local laws and regulations.

The healthcare industry, including the genetic screening market, is subject to extensive and frequently changing international and United States federal, state and local laws and regulations.

This requires that we devote substantial resources to maintaining our compliance with those laws, regulations and standards.

2 unchanged sentences

Our operations are subject to various foreign, federal, state and local environmental and safety laws and regulations.

These requirements include the handling, transportation, manufacture and disposal of toxic or hazardous substances, the remediation of contaminated soil and groundwater, the regulation of radioactive materials, and the health and safety of our employees.

These requirements include the handling, transportation, manufacture and disposal of toxic or hazardous substances, the

remediation of contaminated soil and groundwater, the regulation of radioactive materials, and the health and safety of our employees.

We may have liability under the Comprehensive Environmental Response Compensation and Liability Act and comparable state statutes that impose liability for investigation and remediation of contamination without regard to fault, in connection with materials that we or our former businesses sent to various third-party sites.

2 unchanged sentences

We accrue for environmental issues in the accounting period that our responsibility is established and when the cost can be reasonably estimated.

We have accrued $14.1 million and $12.2 million as of December 31, 2023 and January 1, 2023, respectively, which represents our management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims.

We have accrued $14.2 million and $14.1 million as of December 29, 2024 and December 31, 2023, respectively, which represents our management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims.

Our environmental accrual is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements.

11 unchanged sentences

Several of our subsidiaries outside the United States have employment contracts with our employees where the terms and conditions are influenced by labor unions and workers’ councils’ agreements that involve approximately 4,000 of our employees.

During fiscal year 2023, our voluntary turnover rate was 10%.

We believe that management of our human capital resources is vital to the continued growth and success of our company, and we endeavor to create an environment that encourages productivity, rewards performance and values diversity.

During fiscal year 2024, our voluntary turnover rate was approximately 9%.

There are several ways in which we attempt to attract, develop and retain highly qualified employees, as set forth below.

Our human capital objectives include, as applicable, identifying, recruiting, developing, retaining, incentivizing, and integrating our existing and new employees.

We strive to meet this objective by offering competitive compensation and benefits, in a diverse, inclusive and safe workplace, with opportunities for our employees to grow and develop in their careers.

We strive to meet this objective by offering competitive compensation and benefits, in a safe and rewarding workplace, with opportunities for our employees to grow and develop in their careers.

We hold our employees to high performance standards and our compensation plans are designed to deliver competitive base pay and attractive incentive opportunities.

1 unchanged sentence

We benchmark for market practices and adjust our compensation and benefits programs to ensure they remain both equitable and competitive.

Diversity and Inclusion

We believe in an inclusive workforce, where employees from a number of cultures and countries are engaged and encouraged to leverage their collective talents.

Fostering a Positive Workplace Culture

We believe in a workplace, where everyone feels valued, respected, and has the opportunity to contribute their unique perspectives and talents.

We have employees in roughly 40 countries around the world.

As of the date of filing of this annual report on Form 10-K, women comprised roughly 40% of our leadership positions on a global basis, which we define as director level and above.

We have provided further information regarding our diversity demographics in our Environmental, Social, and Governance (ESG) Report and elsewhere on our website at esg.revvity.com, including summarized data from our EEO-1 form.

esg.revvity.com is a home for information related to ESG policies and initiatives at Revvity.

The site provides information for our employees, customers and investors on our environmental and social metrics and policies, our global efforts to preserve our environment and our global efforts to promote social equality.

It helps our employees and stakeholders know and understand of our commitment to make positive impacts on our employees, customers, local communities and the environment, while engaging others in our efforts.

Our EEO-1 form is a report filed with the United States Equal Employment Opportunity Commission describing the racial, ethnic and gender composition of our U.S.-based workforce.

Information on our website, including the ESG Report, shall not be deemed incorporated by reference into this annual report.

esg.revvity.com is a home for information related to Environmental, Social, and Governance policies and initiatives at Revvity.

The site provides information for our employees, customers and investors on our environmental and social performance, including key metrics and relevant policies.

We highlight our global efforts to preserve our environment, support the communities where we operate, and foster a positive workplace.

The site showcases our commitment to responsible business practices and how these contribute to long-term value creation for our stakeholders.

We understand that our ability to operate in a multicultural world is critical to our long-term value creation.

By maintaining a culture of diversity and inclusion, we believe that we can innovate more effectively.

To that end, we seek to promote diverse perspectives throughout our organization and are an equal opportunity employer committed to making employment decisions without regard to race, religion, national or ethnic origin, sex, sexual orientation, gender identity or expression, age, disability, protected veteran status or other characteristics protected by law.

Our commitment to diversity is evidenced by the advancement of the vibrant belonging collective formed by our four Employee Resources and Networking groups, now comprising of nearly 700 employees who enjoy this safe and engaging platform for dialogue and empowerment.

During the fiscal year 2023, our groups conducted a series of workshops enhancing the visibility of our Hispanic communities in the workplace, recognizing the dedication of our veteran employees and empowering women to network, develop and share their stories.

We continued to support working parents through our flexible working policies and networking opportunities provided by our Women’s Forum.

These efforts serve as a testament to our dedication to fostering an inclusive workplace.

Our commitment to creating a diverse and inclusive work environment is further validated by our 2023 People Experience Survey in which 85% of our employees felt safe to share their opinions and use their voices, providing over 31,000 comments.

We continued to receive a high score in the area of Diversity and Inclusion.

Amongst other comments, employees shared that they are proud of the emphasis we place on diversity and inclusion and on making our company a place where everyone is valued and respected.

We strive to create a workplace where everyone feels valued and respected, believing that this fosters innovation and enables all employees to contribute fully to our shared goals.

We make employment decisions based on legitimate business needs and in compliance with all applicable laws.

Training and Development

7 unchanged sentences

Our internal mobility program empowers employees to explore many different career options available to them.

Career options vary based on the employee’s aspirations and can include specific project work, stretch assignments, job rotations, mentoring, networking, or internal job changes.

Career options vary based on an employee’s aspirations and can include specific project work, stretch assignments, job rotations, mentoring, networking, or internal job changes.

Lastly, management periodically assesses succession planning for certain key positions and reviews our workforce to identify high potential employees for future growth and development.

8 unchanged sentences

We encourage our employees to support the communities in which they live and where we operate, and to assist in that effort, we fund a long-term charitable matching program for our employees.

In addition, we have established a group comprised of management and subject matter experts at our company to focus on developing and delivering on measurable advancements in the areas of reducing waste, reducing carbon emissions and improving employee engagement and diversity.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business